It’s always nice when a plan comes together - Simon Baker’s call on GSK would be that after correctly predicting that they would settle most outstanding cases in the Zantac litigation for dramatically lower than estimated by the broader market. It was therefore slightly surprising to see the move throughout the day lower after initially opening +7% and we still think this is a buying opportunity for a stock that is c50% cheaper than the rest of the sector! For more winning trades, our Spec Sale…
The content on this site is available to all Redburn clients as part of Redburn Execution’s standard service. It is not considered substantive research and there are no commercial implications to viewing these pages.
Please enter your email address below to view this page. If you are still unable to access the page, please speak to your account manager.